TheranosticTrials.org

Clinical Trial · NCT01240720

A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

Overview

The aim of this Study Protocol is to provide a basis for the clinical development of 131I-F16SIP as an anti-cancer therapeutic agent. The study follows and is greatly motivated by the promising results of a Phase I/II study with a similar investigational drug developed by our Company, 131I-L19SIP, in several Italian centers.

Sponsor

Philogen S.p.A.

Phase

Phase 1/2

Contacts

Maddalena Sansovini, Dr (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01240720

Drug / Compound

F16SIP

Isotope(s):
Target(s):
  • Tenascin-C
Ligand Class: Antibodies

F16SIP

Isotope(s):
Target(s):
  • Tenascin-C
Ligand Class: Antibodies

Eligibility

Inclusion

  • All acute toxic effects (excluding alopecia) of any prior therapy (including surgery radiation therapy, chemotherapy) must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v.3.0) Grade ≤ 1.
  • If of childbearing potential, agreement to use adequate contraceptive methods (e.g., oral contraceptives, condoms, or other adequate barrier controls, intrauterine contraceptive devices, or sterilization) beginning at the screening visit and continuing until 3 months following last treatment with study drug.
  • Negative serum pregnancy test for females of childbearing potential within 14 days of starting treatment.
  • Life expectancy of at least 3 months.
  • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
  • Phase I: Patients with cancer, with progressive disease in pre-study period, refractory to conventional standard treatments. Solid Tumor: Histologically/cytologically confirmed diagnosis of cancer, preferably lung cancer, prostate cancer or colorectal cancer (CRC). At least one measurable (minimum 2.0 cm), non irradiated lesion defined according to modified RECIST criteria i.e. whenever the measurable disease is restricted to a solitary lesion, its neoplastic nature need not be confirmed by cytology/histology. Lymphoproliferative Diseases: Histologically/cytologically confirmed diagnosis of lymphoproliferative disease. At least one measurable (minimum 2.0 cm) non irradiated lesion defined according to modified RECIST criteria, i.e. whenever the measurable disease is restricted to a solitary lesion; its neoplastic nature needs to be confirmed by cytology/histology. Phase II: Patients with lymphoma, breast cancer or lung cancer with progressive disease in pre-study period, refractory to conventional standard treatments, will be enrolled in the study. Presence of brain metastases at time of screening does not represent an exclusion criterion. Lesions will be evaluated according to RECIST for solid tumors or to the Revised response criteria for malignant lymphoma (Cheson BD, JCO 2007, 25, 579-58) for lymphomas.
  • ECOG performance status grade 0 or 1.
  • Adequate haematological, liver and renal function (haemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1.50 x 109/L; platelets ≥ 100 x 109/L, bilirubin within UNL; alkaline phosphatase≤ 2.5 x UNL; ALT, AST ≤ UNL or ≤ 2.5 x UNL in case of liver metastases; albumin ≥ 2.5 g/dL; creatinine ≤ UNL.

Exclusion

  • Chemotherapy, radiation, hormonotherapy or immunotherapy or participation in any investigational drug study within 4 weeks of RIT treatment at the RD (6 weeks in case of prior nitroureas chemotherapy).
  • Prior radiation dose \> 30% of bone marrow volume.
  • Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.
  • Presence of cirrhosis or active hepatitis.
  • Presence of serious cardiac (congestive heart failure, heart insufficiency \> grade II NYHA, angina pectoris, myocardial infarction within one year prior to study entry, uncontrolled hypertension or arrhythmia), neurological or psychiatric disorders.
  • Active infection or incomplete wound healing.
  • Recovery from major trauma including surgery within 4 weeks of administration of study treatment.
  • Presence of uncontrolled intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study.
  • Pregnancy or lactation or unwillingness to use adequate method of birth control.
  • Known history of allergy to intravenously administered proteins / peptides / antibodies.